The Cancer Imaging Archive

CPTAC-LUAD | The Clinical Proteomic Tumor Analysis Consortium Lung Adenocarcinoma Collection

DOI: 10.7937/K9/TCIA.2018.PAT12TBS | Data Citation Required | 847 Views | 20 Citations | Image Collection

Summary

This collection contains subjects from the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium Lung Adenocarcinoma (CPTAC-LUAD) cohort. CPTAC is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. Radiology and pathology images from CPTAC patients are being collected and made publicly available by The Cancer Imaging Archive to enable researchers to investigate cancer phenotypes which may correlate to corresponding proteomic, genomic and clinical data.

Imaging from each cancer type will be contained in its own TCIA Collection, with the collection name "CPTAC-cancertype".  Radiology imaging is collected from standard of care imaging performed on patients immediately before the pathological diagnosis, and from follow-up scans where available.  For this reason the radiology image data sets are heterogeneous in terms of scanner modalities, manufacturers and acquisition protocols. Pathology imaging is collected as part of the CPTAC qualification workflow.  

All CPTAC cohorts are released as either a single combined cohort, or split into Discovery and Confirmatory where applicable.  There are two main types of proteomic studies: discovery proteomics and targeted proteomics. The term "discovery proteomics" is in reference to "untargeted" identification and quantification of a maximal number of proteins in a biological or clinical sample. The term “targeted proteomics” refers to quantitative measurements on a defined subset of total proteins in a biological or clinical sample, often following the completion of discovery proteomics studies to confirm interesting targets selected. Commonly used proteomic technologies and platforms are different types of mass spectrometry and protein microarrays depending on the needs, throughput and sample input requirement of an analysis, with further development on nanotechnologies and automation in the pipeline in order to improve the detection of low abundance proteins, increase throughput, and selectively reach a target protein in vivo.  Once the protein targets of interest are identified, high-throughput targeted assays are developed for confirmatory studies: tests to affirm that the initial tests were accurate. A summary of CPTAC imaging efforts can be found on the CPTAC Imaging Proteomics page. 

CPTAC Imaging Special Interest Group

You can join the CPTAC Imaging Special Interest Group to be notified of webinars & data releases, collaborate on common data wrangling tasks and seek out partners to explore research hypotheses!  Artifacts from previous webinars such as slide decks and video recordings can be found on the CPTAC SIG Webinars page.

On July 22, 2020 Shankha Satpathy presented about the consortium's proteogenomic analyses of CPTAC-LUAD.  This deep dive into the LUAD genomic and proteomic datasets will help researchers better understand how these can be correlated with features derived from the imaging data. (Download the slides)

Data Access

Version 12: Updated 2023/02/24

Radiology modality data cleanup to remove extraneous scans.

Additional Resources for this Dataset

The NCI Cancer Research Data Commons (CRDC) provides access to additional data and a cloud-based data science infrastructure that connects data sets with analytics tools to allow users to share, integrate, analyze, and visualize cancer research data.

• Imaging Data Commons (IDC) (Imaging Data)
• Proteomic Data Commons (PDC) (Proteomic & Clinical Data)
• Genomic Data Commons (GDC) (Genomic & Clinical Data)

Citations & Data Usage Policy

Data Citation Required: Users must abide by the TCIA Data Usage Policy and Restrictions. Attribution must include the following citation, including the Digital Object Identifier: